Kawai Masaaki, Suzuki Akihiko, Nishino Yoshikazu, Ohnuki Koji, Ishida Takanori, Amari Masakazu, Shibuya Daisuke, Ohuchi Noriaki
Department of Surgical Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Breast Cancer. 2014 Sep;21(5):542-9. doi: 10.1007/s12282-012-0434-2. Epub 2012 Dec 14.
The effectiveness of screening mammography (MMG) has mainly been demonstrated by studies in western countries. This study was conducted to evaluate cumulative survival and the risk of breast cancer death among Japanese women aged 40-69 years with screening-detected and interval breast cancer divided into three groups: MMG with clinical breast examination (CBE), CBE alone, and self-detection.
By matching a list of 126,537 women (358,242 person-screenings) who participated in the Miyagi Cancer Society Screening program between 1 April 1995 and 31 December 2002 with the Miyagi Prefectural Cancer Registry, 429 MMG with CBE, 522 CBE, and 3,047 self-detected cases were included in this study. Follow-up was performed until the date of death or 31 December 2007. Survival was estimated by the Kaplan-Meier method. The Cox proportional hazards model was used to estimate hazard ratios (HR) and 95 % confidence intervals (CI) for breast cancer death.
Five-year survival for women in the MMG with CBE, CBE, and self-detection groups was 96.8, 92.7, and 86.6 %, respectively. The HR (95 % CI) for breast cancer death was 2.38 (0.72-7.94) among CBE-screened and 4.44 (1.42-13.89) among self-detected cases for women aged 40-49 years, but was 3.00 (1.63-5.50) among CBE-screened and 4.51 (2.69-7.56) among self-detected cases for women aged 50-69 years relative to cases screened by use of MMG with CBE.
In terms of the survival and risk of breast cancer death, MMG with CBE may be more effective than MMG alone or self-detection for Japanese women aged 40-69 years.
乳腺钼靶筛查(MMG)的有效性主要在西方国家的研究中得到证实。本研究旨在评估40 - 69岁日本女性中,筛查发现的乳腺癌和间隔期乳腺癌分为三组:联合临床乳腺检查(CBE)的MMG、单纯CBE以及自我检测的累积生存率和乳腺癌死亡风险。
通过将1995年4月1日至2002年12月31日期间参加宫城县癌症协会筛查项目的126,537名女性(358,242人次筛查)名单与宫城县癌症登记处进行匹配,本研究纳入了429例联合CBE的MMG、522例单纯CBE以及3047例自我检测的病例。随访至死亡日期或2007年12月31日。采用Kaplan-Meier法估计生存率。使用Cox比例风险模型估计乳腺癌死亡的风险比(HR)和95%置信区间(CI)。
联合CBE的MMG组、单纯CBE组和自我检测组女性的五年生存率分别为96.8%、92.7%和86.6%。40 - 49岁女性中,单纯CBE筛查病例的乳腺癌死亡HR(95%CI)为2.38(0.72 - 7.94),自我检测病例为4.44(1.42 - 13.89);而50 - 69岁女性中,单纯CBE筛查病例的乳腺癌死亡HR为3.00(1.63 - 5.50),自我检测病例为4.51(2.69 - 7.56),相对于联合CBE的MMG筛查病例。
就生存率和乳腺癌死亡风险而言,对于40 - 69岁的日本女性,联合CBE的MMG可能比单纯MMG或自我检测更有效。